Stay updated on Pembrolizumab & Cetuximab in HNSCC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Cetuximab in HNSCC Clinical Trial page.

Latest updates to the Pembrolizumab & Cetuximab in HNSCC Clinical Trial page
- Check6 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check13 days agoChange Detected- Revision tag updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedHypopharynx cancer and Oropharynx cancer were added to the Conditions list, and a Genetic and Rare Diseases Information Center resource was added under Resources.SummaryDifference0.2%

- Check42 days agoChange DetectedAdded site revision note: Revision v3.4.2. Removed older notices (Revision v3.4.1) and the funding-status message; no trial data or core page content was altered.SummaryDifference0.4%

- Check49 days agoChange DetectedThe study status was updated to Completed with revised completion and enrollment details, and a government funding/operating-status notice was added.SummaryDifference0.8%

- Check56 days agoChange DetectedAdded a 'Show glossary' option and updated QC metadata to 'Last Update Submitted that Met QC Criteria' with revision 'v3.4.0'; removed the older QC label variants and the 'Revision: v3.3.4' label.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab & Cetuximab in HNSCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Cetuximab in HNSCC Clinical Trial page.